☆Saturn V Capital Management LP
Quality Q
0.730
AUM ($M)
697
Positions
23
Turnover
0.13
Top-10 wt
76%
Herfindahl
0.070
History (qtrs)
6
Excess Return
—
AI Eval Run AI Eval
Holdings · 24 positions · portfolio value $697M
| Ticker | Name | Activity | Security Type | Weight | Δ Weight | Value ($M) | Shares | Δ Shares | Qtrs Held | Excess Return |
|---|---|---|---|---|---|---|---|---|---|---|
| ☆AMLX funds › | AMYLYX PHARMACEUTICALS INC | ADD | — | 11.9% | +1.0% | 83.0 | 4,624,101 | +274,216 | 5 | — |
| ☆ALMS funds › | ALUMIS INC | TRIM | — | 11.8% | -1.0% | 82.0 | 2,915,443 | -286,632 | 3 | — |
| ☆ABVX funds › | ABIVAX SA | TRIM | — | 9.9% | -1.0% | 69.1 | 518,865 | -23,831 | 5 | — |
| ☆PCVX funds › | VAXCYTE INC | ADD | — | 7.1% | -1.6% | 49.6 | 852,914 | +28,382 | 5 | — |
| ☆IMMX funds › | IMMIX BIOPHARMA INC | ADD | — | 6.9% | +0.8% | 48.0 | 4,658,429 | +964,844 | 3 | — |
| ☆PHVS funds › | PHARVARIS N V | ADD | — | 6.5% | +0.4% | 45.4 | 1,314,122 | +112,720 | 4 | — |
| ☆JAZZ funds › | JAZZ PHARMACEUTICALS PLC | TRIM | — | 5.6% | -0.0% | 38.8 | 160,938 | -2,023 | 5 | — |
| ☆CELC funds › | CELCUITY INC | ADD | — | 5.6% | -0.3% | 38.7 | 370,318 | +88,414 | 5 | — |
| ☆IRON funds › | DISC MEDICINE INC | ADD | — | 5.5% | +0.3% | 38.4 | 524,730 | +74,804 | 5 | — |
| ☆CADL funds › | CANDEL THERAPEUTICS INC | ADD | — | 4.9% | +2.3% | 34.0 | 3,303,686 | +407,098 | 2 | — |
| ☆XFOR funds › | X4 PHARMACEUTICALS INC | ADD | — | 4.7% | -0.2% | 32.6 | 6,973,343 | +516,697 | 3 | — |
| ☆MNPR funds › | MONOPAR THERAPEUTICS INC | TRIM | — | 4.1% | +0.7% | 28.9 | 311,976 | -33,650 | 4 | — |
| ☆DYN funds › | DYNE THERAPEUTICS INC | ADD | — | 3.4% | +0.2% | 23.5 | 1,057,493 | +90,884 | 5 | — |
| ☆TRVI funds › | TREVI THERAPEUTICS INC | NEW | — | 2.8% | +2.8% | 19.6 | 1,052,043 | +1,052,043 | 1 | — |
| ☆ZURA funds › | ZURA BIO LTD | ADD | — | 1.8% | +1.0% | 12.4 | 2,101,119 | +1,361,159 | 2 | — |
| ☆SGMT funds › | SAGIMET BIOSCIENCES INC | NEW | — | 1.6% | +1.6% | 11.4 | 1,479,918 | +1,479,918 | 1 | — |
| ☆OCS funds › | OCULIS HOLDING AG | ADD | — | 1.4% | -1.1% | 9.5 | 684,880 | +168,119 | 3 | — |
| ☆IKT funds › | INHIBIKASE THERAPEUTICS INC | ADD | — | 1.1% | -0.0% | 7.9 | 3,869,056 | +5,611 | 3 | — |
| ☆VIR funds › | VIR BIOTECHNOLOGY INC | NEW | — | 1.1% | +1.1% | 7.9 | 770,643 | +770,643 | 1 | — |
| ☆IVVD funds › | INVIVYD INC | TRIM | — | 1.0% | -1.5% | 7.3 | 8,392,288 | -2,556,796 | 3 | — |
| ☆ANRO funds › | ALTO NEUROSCIENCE INC | ADD | — | 0.7% | +0.3% | 4.8 | 182,829 | +93,830 | 2 | — |
| ☆MSLE funds › | SATELLOS BIOSCIENCE INC | HOLD | — | 0.4% | +0.0% | 2.7 | 350,000 | +0 | 2 | — |
| ☆OVID funds › | OVID THERAPEUTICS INC | TRIM | — | 0.3% | -1.4% | 1.8 | 663,060 | -3,503,606 | 3 | — |
| ☆COGT funds › | COGENT BIOSCIENCES INC | EXIT | — | 0.0% | -4.4% | 0.0 | 0 | -626,635 | 0 | — |
Point-in-time history
| Period | AUM ($M) | Positions | Turnover | Top-10 wt | Herfindahl | Quality Q | Skill | Universe |
|---|---|---|---|---|---|---|---|---|
| 2026Q2 | 697 | 23 | 0.13 | 76% | 0.070 | 0.728 | — | in |
| 2026Q1 | 552 | 21 | 0.21 | 77% | 0.073 | 0.569 | — | in |
| 2025Q4 | 545 | 20 | 0.27 | 76% | 0.076 | 0.374 | — | in |
| 2025Q3 | 456 | 17 | 0.28 | 77% | 0.080 | 0.345 | — | in |
| 2025Q2 | 247 | 24 | 0.34 | 69% | 0.059 | 0.152 | — | entered |
| 2025Q1 | 198 | 21 | 0.00 | 77% | 0.078 | 0.000 | — | out |
Long US-equity 13F disclosures only · up to 45-day reporting lag · sells = reduce/avoid, not short.
JSON: /api/signals ·
/api/funds ·
/api/status